NEOCLONE BIOTECHNOLOGY INTERNATIONAL

Company Information

Company Name
NEOCLONE BIOTECHNOLOGY INTERNATIONAL
Address
1202 Ann St
MADISON, WI, 53713-2410
Phone
n/a
URL
n/a
DUNS
19933295
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,640,419.00
6
SBIR Phase II
$206,777.00
1
STTR Phase I
$190,591.00
1
Chart code to be here

Award List

  1. BIOMARK SCRN W REVOLUTIONARY NEOAB ANTIBODIES

    Amount: $100,000.00

    N/A

    SBIR Phase I 2004 Department of Health and Human Services
  2. Novel Platform Technology for Developing Therapeutic Human mAbs

    Amount: $140,000.00

    DESCRIPTION (provided by applicant): Despite significant advances in treatment and early detection, cancer remains a significant disease threat to society. Therapeutic monoclonal antibodies are effect ...

    SBIR Phase I 2007 Department of Health and Human Services
  3. A novel platform for mining the repertoire of antigen-specific B cells

    Amount: $99,635.00

    DESCRIPTION (provided by applicant): Cancer remains a significant threat to the health and economy of today's society. Advances in cancer research are key to cancer biomarker discovery, develop ...

    SBIR Phase I 2007 Department of Health and Human Services
  4. BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

    Amount: $507,208.00

    N/A

    SBIR Phase I 2007 Department of Health and Human Services
  5. BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

    Amount: $507,208.00

    N/A

    SBIR Phase I 2007 Department of Health and Human Services
  6. BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

    Amount: $206,777.00

    Not Available

    SBIR Phase II 2008 Department of Health and Human Services
  7. Improving Ovarian Cancer Treatment by Targeting a Novel Epitope of MUC16

    Amount: $190,591.00

    DESCRIPTION (provided by applicant): The CA125 antigen is a well known marker for monitoring the recurrence and progression of epithelial ovarian cancer. It is now clear that this antigen is a repeati ...

    STTR Phase I 2009 Department of Health and Human Services
  8. Reactivation of human cells for novel fully human Ab platform

    Amount: $286,368.00

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) have been developed into a highly effective class of therapeutic molecules, with global growth of 37% between 2001 and 2002. Since the ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government